SARS-CoV-2 infection protects against rechallenge in rhesus macaques

Chandrashekar, Abishek, Liu, Jinyan, Martinot, Amanda J., McMahan, Katherine, Mercado, Noe B., Peter, Lauren, Tostanoski, Lisa H., Yu, Jingyou +45 more·2020·Science
DOI 10.1126/science.abc4776

Cited by (785)

Items 101–200 of 785

  1. Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers
    S. Marot, I. Malet, V. Leducq, K. Zafilaza, D. Sterlin, D. Planas, A. Gothland, A. Jary, K. Dorgham, T. Bruel et al. · 2021 · Nature Communications
  2. Covid‐19 and dengue: Double punches for dengue‐endemic countries in Asia
    H. Harapan, M. Ryan, B. Yohan, R. S. Abidin, F. Nainu, Ahmed Rakib, Israt Jahan, T. bin Emran, Irfan Ullah, Kritu Panta et al. · 2020 · Reviews in Medical Virology
  3. The humoral response and antibodies against SARS-CoV-2 infection
    Hai Qi, Bo Liu, Xin-Quan Wang, Lin-Qi Zhang · 2022 · Nature Immunology
  4. Implications of Sex Differences in Immunity for SARS-CoV-2 Pathogenesis and Design of Therapeutic Interventions
    Madeleine J. Bunders, Marcus A. Altfeld · 2020 · Immunity
  5. Clinical, immunological and virological characterization of COVID-19 patients that test re-positive for SARS-CoV-2 by RT-PCR
    Jing Lu, Jin-Ju Peng, Qian-Ling Xiong, Zhe Liu, Hui-Fang Lin, Xiao-Hua Tan, Min Kang, Run-Yu Yuan, Lilian Zeng, Pingping Zhou et al. · 2020 · medRxiv
  6. COVID-19 misinformation: Mere harmless delusions or much more? A knowledge and attitude cross-sectional study among the general public residing in Jordan
    Malik Sallam, D. Dababseh, A. Yaseen, A. Al-Haidar, D. Taim, H. Eid, Nidaa A. Ababneh, F. Bakri, A. Mahafzah · 2020 · medRxiv
  7. Phylogenomic analyses provide insights into primate evolution
    Yong Shao, Long Zhou, Fang Li, Lan Zhao, Bao-Lin Zhang, Feng Shao, Jiawei Chen, Chunyan Chen, Xupeng Bi, Xiao-Lin Zhuang et al. · 2023 · Science
  8. Viral load and contact heterogeneity predict SARS-CoV-2 transmission and super-spreading events
    Ashish Goyal, Daniel B. Reeves, Erwing Fabian Cardozo Ojeda, Joshua Tisdell Schiffer, Bryan T. Mayer · 2021 · eLife
  9. Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19
    F. J. Salguero, A. White, G. Slack, S. Fotheringham, Kevin R. Bewley, K. Gooch, S. Longet, H. Humphries, R. Watson, Laura Hunter et al. · 2021 · Nature Communications
  10. Review of infective dose, routes of transmission and outcome of COVID-19 caused by the SARS-COV-2: comparison with other respiratory viruses
    S. Karimzadeh, R. Bhopal, Huy Nguyen Tien · 2021 · Epidemiology and Infection
  11. Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer
    Goshen-Lago, Tal, Waldhorn, Ithai, Holland, Roy, Szwarcwort-Cohen, Moran, Reiner-Benaim, Anat, Shachor-Meyouhas, Yael, Hussein, Khetam, Fahoum, Liana, Baruch, Mali, Peer, Avivit et al. · 2021 · JAMA Oncology
  12. Immunological memory to SARS-CoV-2 assessed for up to eight months after infection
    J. Dan, José Mateus, Y. Kato, K. Hastie, E. Yu, Caterina E. Faliti, A. Grifoni, S. Ramirez, Sonya Haupt, April Frazier et al. · 2020 · bioRxiv
  13. Viral Emerging Diseases: Challenges in Developing Vaccination Strategies
    Maria Trovato, Rossella Sartorius, Luciana D’Apice, Roberta Manco, Piergiuseppe De Berardinis · 2020 · Frontiers in Immunology
  14. Dynamics and significance of the antibody response to SARS-CoV-2 infection
    A. Iyer, Forrest K. Jones, A. Nodoushani, Meagan Kelly, Margaret V Becker, D. Slater, Rachel Mills, E. Teng, M. Kamruzzaman, W. Garcia-Beltran et al. · 2020 · medRxiv
  15. Cellular Immunity in COVID-19 Convalescents with PCR-Confirmed Infection but with Undetectable SARS-CoV-2–Specific IgG
    Sina Schwarzkopf, A. Krawczyk, D. Knop, H. Klump, A. Heinold, F. Heinemann, L. Thümmler, Christian Temme, Marianne Breyer, O. Witzke et al. · 2020 · Emerging Infectious Diseases
  16. Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2
    Kun Xu, Ping Gao, Sheng Liu, Shuaiyao Lu, Wenwen Lei, Tianyi Zheng, Xueyuan Liu, Yufeng Xie, Zhennan Zhao, Shuxin Guo et al. · 2022 · Cell
  17. Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City
    D. Stadlbauer, Jessica Tan, Kai-Jun Jiang, M. Hernandez, Shelcie Fabre, Fatima Amanat, Catherine Teo, G. Arunkumar, Meagan McMahon, Christina Capuano et al. · 2020 · Nature
  18. LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection
    Bryan E. Jones, P. Brown-Augsburger, K. Corbett, Kathryn Westendorf, Julian Davies, T. Cujec, Christopher M. Wiethoff, J. Blackbourne, B. Heinz, Denisa Foster et al. · 2020 · bioRxiv
  19. Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models
    Ku, Min-Wen, Bourgine, Maryline, Authié, Pierre, Lopez, Jodie, Nemirov, Kirill, Moncoq, Fanny, Noirat, Amandine, Vesin, Benjamin, Nevo, Fabien, Blanc, Catherine et al. · 2021 · Cell Host & Microbe
  20. SARS-CoV-2 Infects Endothelial Cells In Vivo and In Vitro
    Feng-Ming Liu, Kun Han, R. Blair, Kornelia Kenst, Zhong-Hua Qin, Berin Upcin, Philipp Wörsdörfer, C. Midkiff, Joseph C. Mudd, E. Belyaeva et al. · 2021 · Frontiers in Cellular and Infection Microbiology
  21. Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses
    Sham Nambulli, Yufei Xiang, N. L. Tilston-Lunel, L. Rennick, Z. Sang, W. Klimstra, D. Reed, N. Crossland, Yi Shi, W. P. Duprex · 2021 · Science Advances
  22. Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine
    Gebre, Makda S., Rauch, Susanne, Roth, Nicole, Yu, Jingyou, Chandrashekar, Abishek, Mercado, Noe B., He, Xuan, Liu, Jinyan, McMahan, Katherine, Martinot, Amanda et al. · 2022 · Nature
  23. T cell response to SARS-CoV-2 infection in humans: A systematic review
    Madhumita Shrotri, May CI van Schalkwyk, Nathan Post, Danielle Eddy, Catherine Huntley, David Leeman, Samuel Rigby, Sarah V Williams, William Hywel Bermingham, Paul Kellam et al. · 2021 · PLoS ONE
  24. Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19
    S. Graham, R. McLean, Alexandra J. Spencer, Sandra Belij-Rammerstorfer, Daniel Wright, Marta Ulaszewska, J. Edwards, Jack W. P. Hayes, Veronica Martini, Nazia Thakur et al. · 2020 · npj Vaccines
  25. Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice
    Natalie Yan‐Lin Pang, Alexander Shao‐Rong Pang, Vincent T. K. Chow, De Yun Wang · 2021 · Military Medical Research
  26. Drug repurposing for COVID-19: Approaches, challenges and promising candidates
    Yan-Ling Ng, Cyrill Kafi Salim, J. Chu · 2021 · Pharmacology and Therapeutics
  27. SARS-CoV-2 specific T cell responses are lower in children and increase with age and time after infection
    Carolyn A. Cohen, Athena P. Y. Li, Asmaa Hachim, David S.C. Hui, Mike Yat Wah Kwan, Owen TY Tsang, Susan Shui Seng Chiu, Wai Hung Chan, Yat Sun Yau, Niloufar Kavian et al. · 2021 · Nature Communications
  28. Molecular Architecture of Early Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major Metropolitan Area
    S. Long, R. Olsen, Paul A. Christensen, David W. Bernard, James J. Davis, M. Shukla, M. Nguyen, M. Saavedra, Prasanti Yerramilli, Layne Pruitt et al. · 2020 · mBio
  29. Features and Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2 Convalescent Individuals
    Butler, Savannah E., Crowley, Andrew R., Natarajan, Harini, Xu, Shiwei, Weiner, Joshua A., Lee, Jiwon, Wieland-Alter, Wendy, Connor, Ruth I., Wright, Peter F., Ackerman, Margaret E. · 2020
  30. Q493K and Q498H substitutions in Spike promote adaptation of SARS-CoV-2 in mice
    Huang, Kun, Zhang, Yufei, Hui, Xianfeng, Zhao, Ya, Gong, Wenxiao, Wang, Ting, Zhang, Shaoran, Yang, Yong, Deng, Fei, Zhang, Qiang et al. · 2021 · EBioMedicine
  31. Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?
    Gregory Milne, Thomas Hames, Chris J. Scotton, Nick Gent, Alexander Johnsen, Roy Malcolm Anderson, Tom Ward · 2021 · The Lancet Respiratory Medicine
  32. Establishment of an African green monkey model for COVID-19 and protection against reinfection
    Courtney B. Woolsey, V. Borisevich, A. Prasad, K. Agans, D. Deer, Natalie S. Dobias, J. Heymann, S. Foster, Corri B. Levine, Liana O. Medina et al. · 2020 · Nature Immunology
  33. Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models
    Khoury, David S., Wheatley, Adam K., Ramuta, Mitchell D., Reynaldi, Arnold, Cromer, Deborah, Subbarao, Kanta, O’Connor, David H., Kent, Stephen J., Davenport, Miles P. · 2020 · Nature Reviews Immunology
  34. Duration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infectivity: When Is It Safe to Discontinue Isolation?
    Chanu Rhee, Sanjat Kanjilal, Meghan A. Baker, Michael Klompas · 2020 · Clinical Infectious Diseases
  35. The scientific and ethical feasibility of immunity passports
    Rebecca C. H. Brown, Dominic F. Kelly, D. Wilkinson, Julian Savulescu · 2020 · Lancet. Infectious Diseases (Print)
  36. Comparison of Subgenomic and Total RNA in SARS-CoV-2-Challenged Rhesus Macaques
    Gabriel Dagotto, N. Mercado, David R. Martinez, Y. Hou, Joseph P. Nkolola, Robert H. Carnahan, J. Crowe, R. Baric, D. Barouch · 2021 · Journal of Virology
  37. Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France
    Fafi-Kremer, Samira, Bruel, Timothée, Madec, Yoann, Grant, Rebecca, Tondeur, Laura, Grzelak, Ludivine, Staropoli, Isabelle, Anna, François, Souque, Philippe, Fernandes-Pellerin, Sandrine et al. · 2020 · eBioMedicine
  38. Intranasal vaccination with lipid-conjugated immunogens promotes antigen transmucosal uptake to drive mucosal and systemic immunity
    B. Hartwell, M. Melo, Peng Xiao, Ashley A. Lemnios, Na Li, Jason Y. H. Chang, Jing-You Yu, Makda S. Gebre, Aiquan Chang, L. Maiorino et al. · 2022 · Science Translational Medicine
  39. Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control
    Shen Wang, Wujian Li, Zhenshan Wang, Wanying Yang, Entao Li, Xianzhu Xia, Feihu Yan, Sandra Chiu · 2024 · Signal Transduction and Targeted Therapy
  40. T cell immunobiology and cytokine storm of COVID‐19
    Xiao-Hua Luo, Yan Zhu, Jian Mao, R. Du · 2020 · Scandinavian Journal of Immunology
  41. Distinct Features and Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2 Convalescent Individuals
    Savannah E. Butler, Andrew R. Crowley, Harini Natarajan, Shiwei Xu, Joshua A. Weiner, Carly A. Bobak, Daniel E. Mattox, Jiwon Lee, Wendy Wieland‐Alter, Ruth I. Connor et al. · 2021 · Frontiers in Immunology
  42. Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection
    Yang Yang, Ming-Hui Yang, Yun Peng, Yan-Jing Liang, Jin-Li Wei, L. Xing, Liping Guo, Xiao-He Li, Jie Li, Jun Wang et al. · 2022 · Nature Microbiology
  43. Approaches and Challenges in SARS-CoV-2 Vaccine Development
    Dagotto, Gabriel, Yu, Jingyou, Barouch, Dan H. · 2020 · Cell Host & Microbe
  44. Animal models in SARS-CoV-2 research
    Chu, Hin, Chan, Jasper Fuk-Woo, Yuen, Kwok-Yung · 2022 · Nature Methods
  45. The immunology of SARS-CoV-2 infections and vaccines
    Lilit Grigoryan, B. Pulendran · 2020 · Seminars in Immunology
  46. Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern
    L. Dupont, L. Snell, C. Graham, J. Seow, B. Merrick, T. Lechmere, T. Maguire, Sadie R. Hallett, S. Pickering, T. Charalampous et al. · 2021 · Nature Microbiology
  47. Future antiviral surfaces: Lessons from COVID-19 pandemic
    Zi-Qi Sun, K. Ostrikov · 2020 · Sustainable Materials and Technologies
  48. Dalbavancin binds ACE2 to block its interaction with SARS-CoV-2 spike protein and is effective in inhibiting SARS-CoV-2 infection in animal models
    Gan Wang, Meng-Li Yang, Zi-Lei Duan, Feng-Liang Liu, Lin Jin, Cheng-Bo Long, Min Zhang, Xiao-Peng Tang, Ling Xu, Ying-chang Li et al. · 2020 · Cell Research
  49. SARS-CoV-2 responsive T cell numbers and anti-Spike IgG levels are both associated with protection from COVID-19: A prospective cohort study in keyworkers
    Wyllie, David, Jones, Hayley E, Mulchandani, Ranya, Trickey, Adam, Taylor-Phillips, Sian, Brooks, Tim, Charlett, Andre, Ades, AE, EDSAB-HOME investigators, Moore, Philippa et al. · 2020
  50. Replication, pathogenicity, and transmission of SARS-CoV-2 in minks
    Lei Shuai, G. Zhong, Q. Yuan, Zhiyuan Wen, Chong Wang, Xi-Jun He, Renqiang Liu, Jin-Liang Wang, Qin-Jian Zhao, Yu-Xiu Liu et al. · 2020 · National Science Review
  51. Biomarkers of COVID-19 and technologies to combat SARS-CoV-2
    Luoping Zhang, Helen Guo · 2020 · Advances in Biomarker Sciences and Technology
  52. Host metabolism dysregulation and cell tropism identification in human airway and alveolar organoids upon SARS-CoV-2 infection
    R. Pei, Jian-Qi Feng, Yecheng Zhang, Hao Sun, Lian Li, Xuejie Yang, Jiang-Ping He, Shuqi Xiao, Jin Xiong, Ying Lin et al. · 2020 · Protein & Cell
  53. Cellular events of acute, resolving or progressive COVID-19 in SARS-CoV-2 infected non-human primates
    Marissa D. Fahlberg, R. Blair, L. Doyle-Meyers, C. Midkiff, Giorgio Zenere, K. Russell-Lodrigue, C. Monjure, E. Haupt, Toni Penney, Gabrielle Lehmicke et al. · 2020 · Nature Communications
  54. COVID-19 mRNA vaccines
    Qing-Rui Huang, Jiawei Zeng, Jing-Hua Yan · 2021 · Journal of genetics and genomics = Yi chuan xue bao
  55. Natural and Experimental SARS-CoV-2 Infection in Domestic and Wild Animals
    D. Meekins, N. Gaudreault, J. Richt · 2021 · Viruses
  56. Deletion of the SARS-CoV-2 Spike Cytoplasmic Tail Increases Infectivity in Pseudovirus Neutralization Assays
    Jing-You Yu, Zhen-Feng Li, Xuan He, Makda S. Gebre, Esther A. Bondzie, Hua-Hua Wan, Catherine Jacob-Dolan, David R. Martinez, Joseph P. Nkolola, R. Baric et al. · 2021 · Journal of Virology
  57. What can we expect from first-generation COVID-19 vaccines?
    M. Peiris, G. M. Leung · 2020 · The Lancet
  58. SARS-CoV-2 S1 and N-based serological assays reveal rapid seroconversion and induction of specific antibody response in COVID-19 patients
    Abdullah Algaissi, Mohamed A. Alfaleh, S. Hala, Turki S. Abujamel, Sawsan S. Alamri, S. Almahboub, Khalid Alluhaybi, H. I. Hobani, Reem M. Alsulaiman, Rahaf H. Alharbi et al. · 2020 · Scientific Reports
  59. A tandem-repeat dimeric RBD protein-based covid-19 vaccine zf2001 protects mice and nonhuman primates
    Yaling An, Shi-Hua Li, Xiyue Jin, Jian-bao Han, Kun Xu, Sen-Yu Xu, Yuxuan Han, Chuan-Yu Liu, Tianyi Zheng, Mei Liu et al. · 2021 · bioRxiv
  60. Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need
    P. Jin, Jingxin Li, H. Pan, Yan-Fei Wu, F. Zhu · 2021 · Signal Transduction and Targeted Therapy
  61. Engineered SARS-CoV-2 receptor binding domain improves manufacturability in yeast and immunogenicity in mice
    N. C. Dalvie, Sergio A. Rodriguez-Aponte, B. Hartwell, Lisa H. Tostanoski, Andrew M. Biedermann, Laura E. Crowell, K. Kaur, Ozan S. Kumru, L. Carter, Jing-You Yu et al. · 2021 · Proceedings of the National Academy of Sciences of the United States of America
  62. A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques
    Ahmed O. Hassan, F. Feldmann, Hai-Yan Zhao, D. Curiel, A. Okumura, Tsing-Lee Tang-Huau, J. Case, Kimberly Meade-White, Julie A. Callison, Rita E. Chen et al. · 2021 · Cell Reports Medicine
  63. Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques
    P. Yadav, Raches Ella, Sanjay Kumar, Dilip R Patil, S. Mohandas, A. Shete, K. M. Vadrevu, Gaurav Bhati, G. Sapkal, H. Kaushal et al. · 2021 · Nature Communications
  64. SARS-CoV-2 infection in nonhuman primates alters the composition and functional activity of the gut microbiota
    H. Sokol, V. Contreras, P. Maisonnasse, A. Desmons, B. Delache, V. Sencio, Arnaud Machelart, Angela Brisebarre, L. Humbert, Lucie Deryuter et al. · 2021 · Gut microbes
  65. Antibody Responses to SARS-CoV-2: Let’s Stick to Known Knowns
    Baumgarth, Nicole, Nikolich-Žugich, Janko, Lee, F Eun-Hyung, Bhattacharya, Deepta · 2020 · The Journal of Immunology
  66. A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques
    Ahmed O. Hassan, F. Feldmann, Hai-Yan Zhao, D. Curiel, A. Okumura, Tsing-Lee Tang-Huau, J. Case, Kimberly Meade-White, Julie A. Callison, J. Lovaglio et al. · 2021 · bioRxiv
  67. Vaccine protection against the SARS-CoV-2 Omicron variant in macaques
    A. Chandrashekar, Jing-You Yu, K. McMahan, Catherine Jacob-Dolan, Jin-Yan Liu, Xuan He, David L. Hope, Tochi Anioke, Julia Barrett, Benjamin Chung et al. · 2022 · bioRxiv
  68. Discrete SARS-CoV-2 antibody titers track with functional humoral stability
    Bartsch, Yannic C., Fischinger, Stephanie, Siddiqui, Sameed M., Chen, Zhilin, Yu, Jingyou, Gebre, Makda, Atyeo, Caroline, Gorman, Matthew J., Zhu, Alex Lee, Kang, Jaewon et al. · 2021 · Nature Communications
  69. Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models
    Kalnin, Kirill V., Plitnik, Timothy, Kishko, Michael, Zhang, Jinrong, Zhang, Donghui, Beauvais, Adrien, Anosova, Natalie G., Tibbitts, Tim, DiNapoli, Josh, Ulinski, Gregory et al. · 2021 · npj Vaccines
  70. Monitoring of SARS‐CoV‐2 infection in mustelids
    A. Boklund, C. Gortázar, P. Pasquali, H. Roberts, S. Nielsen, K. Ståhl, A. Stegeman, Francesca Baldinelli, A. Broglia, Y. Van der Stede et al. · 2021 · EFSA journal. European Food Safety Authority
  71. COVID‐19: Current knowledge in clinical features, immunological responses, and vaccine development
    Ramandeep Singh, A. Kang, Xiang-Qian Luo, M. Jeyanathan, Amy Gillgrass, S. Afkhami, Z. Xing · 2021 · The FASEB Journal
  72. COVID-19 Antibody Tests: A Valuable Public Health Tool with Limited Relevance to Individuals
    Rachel West, Amanda L. Kobokovich, N. Connell, G. Gronvall · 2020 · Trends in Microbiology
  73. Emergency response for evaluating SARS-CoV-2 immune status, seroprevalence and convalescent plasma in Argentina
    D. Ojeda, M. M. Gonzalez Lopez Ledesma, H. Pallarés, Guadalupe S. Costa Navarro, L. Sanchez, B. Perazzi, Sergio M Villordo, D. Álvarez, M. Echavarria, KY Oguntuyo et al. · 2020 · medRxiv
  74. Germline-encoded amino acid-binding motifs drive immunodominant public antibody responses
    Ellen L. Shrock, R. Timms, T. Kula, E. L. Mena, A. West, Rui Guo, I-Hsiu Lee, Alexander A. Cohen, Lindsay G. A. McKay, Cai-Hong Bi et al. · 2023 · Science
  75. Persistence of SARS-CoV-2 in the first trimester placenta leading to transplacental transmission and fetal demise from an asymptomatic mother
    Prajakta Shende, P. Gaikwad, Manisha R. Gandhewar, Pawankumar M. Ukey, A. Bhide, V. Patel, Sharad Bhagat, Vikrant M. Bhor, S. Mahale, Rahul Gajbhiye et al. · 2020 · Human Reproduction
  76. Development and deployment of COVID-19 vaccines for those most vulnerable
    Wayne Chester Koff, Theodore Schenkelberg, Tere M. Williams, Ralph Steven Baric, Adrian B. McDermott, Cheryl Cameron, Mark J. Cameron, Matthew B. Frieman, Gabriele Neumann, Yoshihiro Kawaoka et al. · 2021 · Science Translational Medicine
  77. Nanocarrier vaccines for SARS-CoV-2
    Jatin Machhi, Farah Shahjin, Srijanee Das, Milankumar Patel, M. M. Abdelmoaty, Jacob D. Cohen, P. Singh, Ashish Baldi, N. Bajwa, Raj Kumar et al. · 2021 · Advanced Drug Delivery Reviews
  78. Neutrophils and COVID-19: Active Participants and Rational Therapeutic Targets
    J. Hazeldine, J. Lord · 2021 · Frontiers in Immunology
  79. Mapping the SARS-CoV-2 spike glycoprotein-derived peptidome presented by HLA class II on dendritic cells
    R. Parker, Thomas Partridge, Catherine Wormald, Rebeca Kawahara, V. Stalls, Maria Aggelakopoulou, Jimmy Parker, R. Powell Doherty, Yoanna Ariosa Morejon, Esther M. Lee et al. · 2020 · bioRxiv
  80. T cells in COVID-19 — united in diversity
    Swadling, Leo, Maini, Mala K. · 2020 · Nature Immunology
  81. In Vitro and In Vivo Models for Studying SARS-CoV-2, the Etiological Agent Responsible for COVID-19 Pandemic
    Rafael Borges Rosa, Willyenne Marília Dantas, Jéssica Catarine Frutuoso do Nascimento, Murilo Vieira da Silva, Ronaldo N. de Oliveira, Lindomar Pena · 2021 · Viruses
  82. COVID-19 Vaccines: “Warp Speed” Needs Mind Melds, Not Warped Minds
    John P. Moore, Per Johan Klasse · 2020 · Journal of Virology
  83. Functional characterization of CD4+ T cell receptors crossreactive for SARS-CoV-2 and endemic coronaviruses
    Arbor G. Dykema, Boyang Zhang, Bezawit A. Woldemeskel, Caroline C. Garliss, Laurene S. Cheung, Dilshad M. Choudhury, Jiajia Zhang, Luis Aparicio, Sadhana Bom, Rufiaat Rashid et al. · 2021 · Journal of Clinical Investigation
  84. Obesity may hamper SARS-CoV-2 vaccine immunogenicity
    R. Pellini, Aldo Venuti, F. Pimpinelli, E. Abril, Giovanni Blandino, Flaminia Campo, L. Conti, A. de Virgilio, Federico De Marco, E. D. Di Domenico et al. · 2021 · medRxiv
  85. Protection against SARS-CoV-2 infection by a mucosal vaccine in rhesus macaques
    Y. Sui, Jianping Li, Roushu Zhang, S. Prabhu, H. Andersen, D. Venzon, Anthony Cook, Renita Brown, Elyse Teow, Jason Velasco et al. · 2021 · JCI Insight
  86. SARS-CoV-2-specific circulating T follicular helper cells correlate with neutralizing antibodies and increase during early convalescence
    Sushma Boppana, Kai Qin, Jacob K. Files, Ronnie M. Russell, Regina Stoltz, Frédéric Bibollet‐Ruche, Anju Bansal, Nathan B. Erdmann, Beatrice H. Hahn, Paul Goepfert · 2021 · PLoS Pathogens
  87. An emerging SARS-CoV-2 mutant evading cellular immunity and increasing viral infectivity
    C. Motozono, M. Toyoda, J. Zahradník, T. Ikeda, Akatsuki Saito, T. S. Tan, I. Ngare, H. Nasser, I. Kimura, K. Uriu et al. · 2021 · bioRxiv
  88. Animal models for SARS‐CoV‐2 research: A comprehensive literature review
    Kabita Pandey, Arpan Acharya, Mahesh Mohan, Caroline L. Ng, St Patrick Reid, Siddappa N. Byrareddy · 2020 · Transboundary and Emerging Diseases
  89. SARS-CoV-2 Antiviral Therapy
    Kaiming Tao, Philip L. Tzou, Janin Nouhin, Hector Fabio Bonilla, Prasanna Jagannathan, Robert W. Shafer · 2021 · Clinical Microbiology Reviews
  90. Quantifying absolute neutralization titers against SARS-CoV-2 by a standardized virus neutralization assay allows for cross-cohort comparisons of COVID-19 sera
    KY Oguntuyo, C. Stevens, Chuan-Tien Hung, Satoshi Ikegame, Joshua A. Acklin, S. Kowdle, Jillian C. Carmichael, Hsin-Ping Chiu, Kristopher D. Azarm, Griffin D Haas et al. · 2020 · medRxiv
  91. Type I interferons and SARS-CoV-2: from cells to organisms
    P. Bastard, Qian Zhang, Shen-Ying Zhang, E. Jouanguy, J. Casanova · 2022 · Current Opinion in Immunology
  92. A defective viral genome strategy elicits broad protective immunity against respiratory viruses
    Yinghong Xiao, Peter V. Lidsky, Yuta Shirogane, Ranen Aviner, Chien-Ting Wu, Weiyi Li, Weihao Zheng, Dale Talbot, Adam Catching, Gilad Doitsh et al. · 2021 · Cell
  93. SARS-CoV-2 reinfection and implications for vaccine development
    F. Nainu, R. S. Abidin, M. Bahar, A. Frediansyah, Talha Bin Emran, A. Rabaan, K. Dhama, H. Harapan · 2020 · Human Vaccines & Immunotherapeutics
  94. SARS-CoV-2 induces robust germinal center CD4 T follicular helper cell responses in rhesus macaques
    Yashavanth Shaan Lakshmanappa, Sonny R. Elizaldi, Jamin W. Roh, B. Schmidt, Timothy D. Carroll, Kourtney D. Weaver, Justin C. Smith, A. Verma, J. Deere, Joseph C. Dutra et al. · 2021 · Nature Communications
  95. SARS-CoV-2 Infection: New Molecular, Phylogenetic, and Pathogenetic Insights. Efficacy of Current Vaccines and the Potential Risk of Variants
    John Charles Rotondo, Fernanda Martini, Martina Maritati, Chiara Mazziotta, Giulia Di Mauro, Carmen Lanzillotti, Nicole Barp, Altea Gallerani, Mauro G. Tognon, Carlo Contini · 2021 · Viruses
  96. Dynamics of CD4 T Cell and Antibody Responses in COVID-19 Patients With Different Disease Severity
    Maximilian Koblischke, M. Traugott, Iris Medits, Felicia S. Spitzer, A. Zoufaly, Lukas Weseslindtner, Cara Simonitsch, T. Seitz, W. Hoepler, E. Puchhammer-Stöckl et al. · 2020 · Frontiers in Medicine
  97. Durable SARS-CoV-2 B cell immunity after mild or severe disease
    C. Ogega, Nicole E. Skinner, P. Blair, Han-Sol Park, Kirsten Littlefield, A. Ganesan, Pranay Ladiwala, A. Antar, S. Ray, M. Betenbaugh et al. · 2020 · medRxiv
  98. Host-pathogen interaction in COVID-19: Pathogenesis, potential therapeutics and vaccination strategies
    Praveen Mathews Varghese, Anthony George Tsolaki, Hadida Yasmin, Abhishek Shastri, Janez Ferluga, Manu Vatish, Taruna Madan, Uday Kishore · 2020 · Immunobiology
  99. Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques
    He, Xuan, Chandrashekar, Abishek, Zahn, Roland, Wegmann, Frank, Yu, Jingyou, Mercado, Noe B., McMahan, Katherine, Martinot, Amanda J., Piedra-Mora, Cesar, Beecy, Sidney et al. · 2021 · Cell
  100. Waning antibody responses in COVID-19: what can we learn from the analysis of other coronaviruses?
    Ali Hamady, JinJu Lee, Zuzanna Loboda · 2021 · Infection